Bioline Celebrates 20 Years of Service to Life Science
News Mar 20, 2012
The PCR reagents portfolio includes all components required for PCR and real-time PCR: DNA polymerases and master mixes, reverse transcriptases, nucleotides, buffers and additives. Bioline’s PCR and real-time PCR products are thoroughly validated with all the major instrument systems on the market.
Marco Calzavara, President of Meridian Bioscience Europe, commented, “Our aim at Bioline for the past 20 years has been to develop high-quality and reliable products that make the difference, delivering consistent results time after time. I am excited to carry on Bioline’s great work as a cutting edge molecular biology company, ensuring that we maintain our reputation as a high-quality and reliable firm.”
Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience, Inc., stated, “Congratulations to the Bioline team on its 20th anniversary of successful operations throughout the world. We are enthusiastic about the success of the merger and impressed by the scientific capabilities of Bioline, as well as, its well-deserved reputation for innovation and quality. We remain committed to expanding the rapidly growing portfolio of highly specialized molecular biology products from Bioline that enable the development of genomic tests utilized by researchers, clinical diagnostic laboratories, diagnostic test manufacturers and biotechnology companies.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.